Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| AOD-9604 | IGF-1 LR3 | |
|---|---|---|
| Category | Growth Factors | Growth Factors |
| Standard Dose | Research indicates 250-300 mcg daily via subcutaneous injection, administered in the morning on an empty stomach. | Research indicates 20-50 mcg daily via subcutaneous or intramuscular injection. |
| Timing | Morning administration on empty stomach, at least 30 minutes before eating. Fasted state enhances lipolytic effect. | Post-workout administration for muscle growth. Can be injected locally (intramuscularly) into target muscle groups. Morning dosing on rest days. |
| Cycle Duration | 12-20 week cycles. | 4-6 week cycles maximum. Longer cycles risk significant side effects and receptor desensitization. |
| Evidence Level | moderate_human | moderate_human |
AOD-9604 is a synthetic 16-amino acid fragment (residues 176-191) of the C-terminal domain of human growth hormone with a tyrosine substitution at the N-terminus. It selectively stimulates lipolysis by upregulating beta-3 adrenergic receptors in adipose tissue while inhibiting lipogenesis. It modulates lipid and glucose metabolism through beta-adrenergic and AMPK-related pathways without influencing IGF-1 activity, growth, or insulin sensitivity — retaining GH's fat-burning properties without its growth-promoting effects.
Research indicates 250-300 mcg daily via subcutaneous injection, administered in the morning on an empty stomach.
Morning administration on empty stomach, at least 30 minutes before eating. Fasted state enhances lipolytic effect.
12-20 week cycles.
IGF-1 LR3 (Long Arginine 3-IGF-1) is an 83-amino acid synthetic analog of IGF-1 with an arginine substitution at position 3 and 13 additional N-terminal amino acids. These modifications eliminate binding to IGF-binding proteins, making it approximately 3x more potent than native IGF-1 with a half-life of 20-30 hours (vs 12-15 minutes for native IGF-1). It activates the IGF-1R tyrosine kinase receptor, triggering IRS-1/PI3K/Akt/mTOR and PI3K/Akt/GSK3-beta pathways to drive protein synthesis, muscle hypertrophy, and hyperplasia (new muscle cell formation).
Research indicates 20-50 mcg daily via subcutaneous or intramuscular injection.
Post-workout administration for muscle growth. Can be injected locally (intramuscularly) into target muscle groups. Morning dosing on rest days.
4-6 week cycles maximum. Longer cycles risk significant side effects and receptor desensitization.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →